Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067933 · ClinicalTrials.gov registry record · Phase 2
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
A Phase 2 study, sponsored by Vaxart.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT05067933 is a Phase 2 study that was terminated before completion, run by Vaxart. The registered enrollment target is 66 participants.
The verdict
NCT05067933, a Phase 2 study, was terminated before completion, sponsored by Vaxart.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19. Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.
Interventions
- OTHER Placebo Tablets
- DRUG VXA-CoV2-1.1-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05067933
The ClinicalTrials.gov registry entry for NCT05067933 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Tablets is the first listed.
NCT05067933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05067933 about?
NCT05067933 is a clinical study titled "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine". Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid)...
What is the current status of trial NCT05067933?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2021-10-22. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05067933?
The interventions under investigation include: Placebo Tablets (OTHER), VXA-CoV2-1.1-S (DRUG).
Who is sponsoring clinical trial NCT05067933?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.